HC Wainwright Issues Pessimistic Outlook for OCUL Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Analysts at HC Wainwright cut their FY2026 EPS estimates for Ocular Therapeutix in a research report issued on Tuesday, November 10th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will earn ($1.62) per share for the year, down from their previous forecast of ($1.49). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.47) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.87) EPS.

Several other brokerages have also issued reports on OCUL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, October 15th. Chardan Capital restated a “buy” rating and set a $23.00 target price on shares of Ocular Therapeutix in a report on Friday, October 2nd. UBS Group assumed coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They issued a “buy” rating and a $14.00 price objective for the company. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Monday, October 19th. Finally, Zacks Research raised Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus price target of $23.83.

Ocular Therapeutix Stock Up 0.8%

OCUL stock opened at $6.66 on Thursday. Ocular Therapeutix has a 12 month low of $6.00 and a 12 month high of $16.44. The firm has a 50 day moving average of $8.17 and a 200-day moving average of $8.96. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06). Ocular Therapeutix had a negative return on equity of 56.26% and a negative net margin of 648.64%. The business had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.27 million. During the same quarter in the previous year, the business earned ($0.38) EPS. Ocular Therapeutix’s revenue for the quarter was down 11.5% on a year-over-year basis.

Institutional Investors Weigh In On Ocular Therapeutix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC purchased a new stake in shares of Ocular Therapeutix in the second quarter valued at $51,000. Sterling Capital Management LLC increased its position in Ocular Therapeutix by 401.7% during the 3rd quarter. Sterling Capital Management LLC now owns 6,612 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 5,294 shares during the period. Root Financial Partners LLC purchased a new position in shares of Ocular Therapeutix in the 3rd quarter valued at $66,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ocular Therapeutix during the 3rd quarter worth approximately $86,000. Finally, Trust Co. of Vermont acquired a new position in Ocular Therapeutix during the 2nd quarter valued at about $112,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Ocular Therapeutix

In related news, insider Todd Anderman sold 11,984 shares of the stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $7.29, for a total value of $87,363.36. Following the completion of the sale, the insider directly owned 140,484 shares of the company’s stock, valued at approximately $1,024,128.36. This represents a 7.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Peter Kaiser sold 9,990 shares of the stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the completion of the sale, the insider owned 254,388 shares of the company’s stock, valued at $1,793,435.40. The trade was a 3.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 98,090 shares of company stock worth $787,920 in the last quarter. 3.10% of the stock is currently owned by insiders.

Key Ocular Therapeutix News

These are some of the OCUL news items that stood out recently:

• Positive Sentiment: HC Wainwright raised its price target to $28 from $25 and reiterated its Buy rating, signaling substantial upside in the analyst’s view. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright
• Positive Sentiment: Recent coverage highlighted Phase 3 success in wet age-related macular degeneration, a potential catalyst for Ocular’s AXPAXLI program and investor optimism. Investors Reacting to Ocular Therapeutix Phase 3 Wet AMD Success
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for multiple quarters and full years, including FY2026 to a loss of $1.62 per share from $1.49 and FY2027 to a loss of $1.87 from $1.54. The cuts suggest a longer or deeper period of losses, although the firm maintained its Buy rating and $28 target.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.